The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Intravenous Nefopam Reduces Postherpetic Neuralgia during the Titration of Oral Medications

  • Joo, Young Chan (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Ko, Eun Sung (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Cho, Jae Geun (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Ok, Young Min (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Jung, Gyu Yong (Department of Plastic Surgery, School of Medicine, Dongguk University) ;
  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • Received : 2013.12.05
  • Accepted : 2013.12.12
  • Published : 2014.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The recently known analgesic action mechanisms of nefopam (NFP) are similar to those of anticonvulsants and antidepressants in neuropathic pain treatment. It is difficult to prescribe high doses of oral neuropathic drugs without titration due to adverse effects. Unfortunately, there are few available intravenous analgesics for the immediate management of acute flare-ups of the chronic neuropathic pain. The aim of this study was to determine the additional analgesic effects for neuropathic pain of NFP and its adverse effects during the titration of oral medications for neuropathic pain among inpatients with postherpetic neuralgia (PHN). Methods: Eighty inpatients with PHN were randomly divided into either the NFP or normal saline (NS) groups. Each patient received a 3-day intravenous continuous infusion of either NFP with a consecutive dose reduction of 60, 40, and 20 mg/d, or NS simultaneously while dose titrations of oral medications for neuropathic pain gradually increased every 3 days. The efficacy of additional NFP was evaluated by using the neuropathic pain symptom inventory (NPSI) score for 12 days. Adverse effects were also recorded. Results: The median NPSI score was significantly lower in the NFP group from days 1 to 6 of hospitalization. The representative alleviating symptoms of pain after using NFP were both spontaneous and evoked neuropathic pain. Reported common adverse effects were nausea, dizziness, and somnolence, in order of frequency. Conclusions: An intravenous continuous infusion of NFP reduces spontaneous and evoked neuropathic pain with tolerable adverse effects during the titration of oral medications in inpatients with PHN.

Keywords

References

  1. Turk DC, Okifuji A. Pain terms and taxonomies. In: Bonica's management of pain. 4th ed. Edited by Fishman SM, Ballantyne JC, Rathmell JP. Philadelphia (PA), Lippincott Williams & Wilkins. 2010, p 16.
  2. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 19: 249-67. https://doi.org/10.2165/00003495-198019040-00001
  3. Novelli A, Díaz-Trelles R, Groppetti A, Fernández-Sánchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005;28: 183-91. https://doi.org/10.1007/s00726-005-0166-0
  4. Verleye M, André N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013:249-55. https://doi.org/10.1016/j.brainres.2004.04.035
  5. Biella GE, Groppetti A, Novelli A, Fernández-Sánchez MT, Manfredi B, Sotgiu ML. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. J Neurotrauma 2003;20: 593-601. https://doi.org/10.1089/089771503767168519
  6. Novelli A, Groppetti A, Rossoni G, Manfredi B, Ferrero-Gutiérrez A, Pérez-Gómez A, et al. Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. Amino Acids 2007; 32: 323-32. https://doi.org/10.1007/s00726-006-0419-6
  7. Czuczwar M, Czuczwar K, Cięszczyk J, Kiś J, Saran T, Łuszczki JJ, et al. Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice. Pharmacol Rep 2011; 63: 690-6. https://doi.org/10.1016/S1734-1140(11)70580-1
  8. Löscher W, Schmidt D. New Horizons in the development of antiepileptic drugs: Innovative strategies. Epilepsy Res 2006;69: 183-272. https://doi.org/10.1016/j.eplepsyres.2006.03.014
  9. Marazziti D, Rotondo A, Ambrogi F, Cassano GB. Analgesia by nefopam: does it act through serotonin? Drugs Exp Clin Res 1991; 17: 259-61.
  10. Evans MS, Lysakowski C, Tramèr MR. Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth 2008; 101: 610-7. https://doi.org/10.1093/bja/aen267
  11. Sunshine A, Laska E. Nefopam and morphine in man. Clin Pharmacol Ther 1975; 18: 530-4. https://doi.org/10.1002/cpt1975185part1530
  12. Taniguchi Y, Ali SZ, Kimberger O, Zmoos S, Lauber R, Markstaller M, et al. The effects of nefopam on the gain and maximum intensity of shivering in healthy volunteers. Anesth Analg 2010; 111: 409-14. https://doi.org/10.1213/ANE.0b013e3181e332bb
  13. Alfonsi P, Passard A, Gaude-Joindreau V, Guignard B, Sessler DI, Chauvin M. Nefopam and alfentanil additively reduce the shivering threshold in humans whereas nefopam and clonidine do not. Anesthesiology 2009; 111: 102-9. https://doi.org/10.1097/ALN.0b013e3181a979c1
  14. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108:248-57. https://doi.org/10.1016/j.pain.2003.12.024
  15. Thakur R, Kent JL, Dworkin RH. Herpes zoster and postherpetic neuralgia. In: Bonica's management of pain. 4th ed. Edited by Fishman SM, Ballantyne JC, Rathmell JP. Philadelphia (PA), Lippincott Williams & Wilkins. 2010, pp 338-57.
  16. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol 2013; 13: 292-307. https://doi.org/10.1136/practneurol-2013-000536
  17. Attal N. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials. Continuum (Minneap Minn) 2012; 18: 161-75.
  18. Costigan M, Woolf CJ. Pain: molecular mechanisms. J Pain 2000; 1(3 Suppl): 35-44.
  19. Durrieu G, Olivier P, Bagheri H, Montastruc JL; French Network of Pharmacovigilance Centers. Overview of adverse reactions to nefopam: an analysis of the French pharmacovigilance database. Fundam Clin Pharmacol 2007; 21:555-8. https://doi.org/10.1111/j.1472-8206.2007.00499.x

Cited by

  1. Medications in Treatment of Postherpetic Neuralgia vol.27, pp.1, 2014, https://doi.org/10.3344/kjp.2014.27.1.1
  2. Nefopam Reduces Dysesthesia after Percutaneous Endoscopic Lumbar Discectomy vol.29, pp.1, 2016, https://doi.org/10.3344/kjp.2016.29.1.40
  3. Use of Nefopam in Perioperative Pain Management; Keeping Nefopam in between vol.29, pp.2, 2016, https://doi.org/10.3344/kjp.2016.29.2.71
  4. Opioid sparing effect and safety of nefopam in patient controlled analgesia after laparotomy: A randomized, double blind study vol.44, pp.4, 2016, https://doi.org/10.1177/0300060516650783
  5. Earlier treatment improves the chances of complete relief from postherpetic neuralgia vol.30, pp.3, 2017, https://doi.org/10.3344/kjp.2017.30.3.214
  6. Analgesic efficacy of nefopam for cancer pain: a randomized controlled study vol.9, pp.None, 2014, https://doi.org/10.12688/f1000research.23455.1
  7. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations vol.176, pp.5, 2014, https://doi.org/10.1016/j.neurol.2020.01.361